Revolution Medicines, Inc. (RVMD) Tops Q2 EPS by 3c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($0.82), $0.03 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $7.02 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.